Skip to main content
Clinical Trials/NL-OMON47824
NL-OMON47824
Recruiting
Phase 3

Stem Cell therapy in IschEmic Non-treatable Cardiac disease - SCIENCE - SCIENCE

Rigshospitalet Copenhagen University Hospital, Capital Region of Denmark0 sites20 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
ischaemic heart failure
Sponsor
Rigshospitalet Copenhagen University Hospital, Capital Region of Denmark
Enrollment
20
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Rigshospitalet Copenhagen University Hospital, Capital Region of Denmark

Eligibility Criteria

Inclusion Criteria

  • 1\. 30 to 80 years of age
  • 2\. Signed informed consent
  • 3\. Chronic stable ischemic heart disease
  • 4\. Symptomatic Heart failure (NYHA II\-III)
  • 5\. LVEF \<\=45% on echocardiography, CT or MRI scan.
  • 6\. Plasma NT\-pro\-BNP \> 300 pg/ml (\> 35 pmol/L)
  • 7\. Maximal tolerable heart failure medication
  • 8\. Medication unchanged two months prior to inclusion/signature of informed
  • consent. Changes in diuretics accepted.
  • 9\. No option for percutaneous coronary intervention (PCI) or coronary artery

Exclusion Criteria

  • Exclusion criteria
  • 1\. Heart Failure (NYHA I or IV)
  • 2\. Acute coronary syndrome with elevation of CKMB or troponins, stroke or
  • transitory cerebral ischemia within six weeks of inclusion. Constant elevated
  • troponin due to renal failure, heart failure etc. do not exclude the patient.
  • 3\. Other revascularisation treatment within four months of treatment
  • 4\. If clinically indicated the patient should have a coronary angiography
  • before inclusion
  • 5\. Moderate to severe aortic stenosis (valve area \< 1\.3 cm2\) or
  • valvular disease with option for surgery or interventional therapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials